Journal of Thrombosis and Haemostasis, 1538-7933

Tidskrift

Fler filtreringsmöjligheter
  1. Prophylaxis Escalation in Severe von Willebrand Disease: A Prospective Study from the von Willebrand Disease Prophylaxis Network.

    T Abshire, J Cox-Gill, C L Kempton, F W G Leebeek, M Carcao, P Kouides, S Donfield & Erik Berntorp, 2015, I : Journal of Thrombosis and Haemostasis. 13, 9, s. 1585-1589

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  2. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following IV administration in haemophilia patients.

    H Agersø, D F Brophy, H Pelzer, E J Martin, M Carr, Ulla Hedner & M Ezban, 2011, I : Journal of Thrombosis and Haemostasis. 9, 2, s. 333-338

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  3. Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding

    E Ajzner, I Balogh, G Haramura, Z Boda, K Kalmar, G Pfliegler, Björn Dahlbäck & L Muszbek, 2003, I : Journal of Thrombosis and Haemostasis. 1, 5, s. 943-949

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  4. Are randomized clinical trials the only truth? Not always

    L Aledort, Rolf Ljung & V Blanchette, 2006, I : Journal of Thrombosis and Haemostasis. 4, 3, s. 503-504

    Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

  5. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A

    Jan Astermark, X. Wang, J. Oldenburg, Erik Berntorp & A. -K. Lefvert, 2007, I : Journal of Thrombosis and Haemostasis. 5, 2, s. 263-265

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  6. The von Willebrand disease prophylaxis network: exploring a treatment concept.

    Erik Berntorp & T Abshire, 2006, I : Journal of Thrombosis and Haemostasis. 4, 11, s. 2511-2512

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  7. Definitions in hemophilia: communication from the SSC of the ISTH

    V. S. Blanchette, N. S. Key, Rolf Ljung, M. J. Manco-Johnson, H. M. Van Den Berg & A. Srivastava, 2014, I : Journal of Thrombosis and Haemostasis. 12, 11, s. 1935-1939

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  8. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin (R)): a prospective study of 50 patients

    A. Borel-Derlon, A. B. Federici, V. Roussel-Robert, J. Goudemand, C. A. Lee, I. Scharrer, C. Rothschild, Erik Berntorp, C. Henriet, Z. Tellier, F. Bridey & P. M. Mannucci, 2007, I : Journal of Thrombosis and Haemostasis. 5, 6, s. 1115-1124

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  9. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: A two-center study

    A. E. Bowyer, A. Hillarp, M. Ezban, P. Persson & S. Kitchen, 2016, I : Journal of Thrombosis and Haemostasis. 14, 7, s. 1428-1435

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  10. Population Pharmacokinetics of Plasma-Derived Factor IX: Procedures for Dose Individualization.

    Ari Brekkan, Erik Berntorp, Kirsten Jensen, Elisabet I Nielsen & Siv Jönsson, 2016, I : Journal of Thrombosis and Haemostasis. 14, 4, s. 724-732

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  11. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)

    U Budde, R Schneppenheim, J Eikenboom, A Goodeve, K Will, E Drewke, G Castaman, F Rodeghiero, A B Federici, J Batlle, A Perez, D Meyer, C Mazurier, J Goudemand, J Ingerslev, D Habart, Z Vorlova, Lars Holmberg, Stefan Lethagen, J Pasi & 2 andra, F Hill & I Peake, 2008, I : Journal of Thrombosis and Haemostasis. 6, 5, s. 762-771

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  12. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study

    G. Castaman, F. Rodeghiero, A. Tosetto, A. Cappelletti, F. Baudo, J. C. J. Eikenboom, A. B. Federici, Stefan Lethagen, S. Linari, J. Lusher, M. Nishino, P. Petrini, A. Srivastava & J. S. Ungerstedt, 2006, I : Journal of Thrombosis and Haemostasis. 4, 10, s. 2164-2169

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  13. Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa.

    C A Clark, R Vatsyayan, Ulla Hedner, C T Esmon, U R Pendurthi & L V M Rao, 2012, I : Journal of Thrombosis and Haemostasis. 10, 11, s. 2383-2391

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  14. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

    P. W. Collins, V. S. Blanchette, K. Fischer, S. Bjorkman, M. Oh, S. Fritsch, P. Schroth, G. Spotts, Jan Astermark & B. Ewenstein, 2009, I : Journal of Thrombosis and Haemostasis. 7, 3, s. 413-420

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  15. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.

    P W Collins, J Møss, Karin Knobe, A Groth, T Colberg & E Watson, 2012, I : Journal of Thrombosis and Haemostasis. 10, 11, s. 2305-2312

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  16. The discovery of activated protein C resistance.

    Björn Dahlbäck, 2003, I : Journal of Thrombosis and Haemostasis. 1, 1, s. 3-9

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  17. Molecular recognition in the protein C anticoagulant pathway.

    Björn Dahlbäck & B O Villoutreix, 2003, I : Journal of Thrombosis and Haemostasis. 1, 7, s. 1525-1534

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  18. The multiple faces of the partial thromboplastin time APTT.

    Björn Dahlbäck, 2004, I : Journal of Thrombosis and Haemostasis. 2, 12, s. 2256-2257

    Forskningsoutput: TidskriftsbidragLetter

  19. Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S

    B. Dahlbäck, 2017 jul 1, I : Journal of Thrombosis and Haemostasis. 15, 7, s. 1241-1250 10 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  20. New functional test for the TFPIα cofactor activity of Protein S working in synergy with FV-Short

    Björn Dahlbäck, Li Jun Guo, Bengt Zöller & Sinh Tran, 2019, I : Journal of Thrombosis and Haemostasis. 17, 4, s. 585-595

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  21. The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A

    C. L. Eckhardt, Jan Astermark, S. Q. Nagelkerke, J. Geissler, M. W. T. Tanck, M. Peters, K. Fijnvandraat & T. W. Kuijpers, 2014, I : Journal of Thrombosis and Haemostasis. 12, 8, s. 1294-1301

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  22. Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination - a rebuttal

    N Egberg, I Fagerberg, Andreas Hillarp, TL Lindahl & L Stigendal, 2005, I : Journal of Thrombosis and Haemostasis. 3, 10, s. 2370-2371

    Forskningsoutput: TidskriftsbidragLetter

  23. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD

    J Eikenboom, V Van Marion, H Putter, A Goodeve, F Rodeghiero, G Castaman, AB Federici, J Batlle, D Meyer, C Mazurier, J Goudemand, R Schneppenheim, U Budde, J Ingerslev, Z Vorlova, D Habart, Lars Holmberg, S Lethagen, J Pasi, F Hill & 1 andra, I Peake, 2006, I : Journal of Thrombosis and Haemostasis. 4, 4, s. 774-782

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  24. Gas6 is complexed to soluble tyrosine kinase receptor Axl in human blood.

    Carl Ekman, Jonas Stenhoff & Björn Dahlbäck, 2010, I : Journal of Thrombosis and Haemostasis. 8, 4, s. 838-844

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  25. Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23 796 consecutive autopsies

    A. Eliasson, D. Bergqvist, M. Bjorck, Stefan Acosta, Nils Sternby & M. Ogren, 2006, I : Journal of Thrombosis and Haemostasis. 4, 9, s. 1897-1902

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  26. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)

    R. Gopalakrishnan, Ulla Hedner, S. Ghosh, R. C. Nayak, T. C. Allen, U. R. Pendurthi & L. V. M. Rao, 2010, I : Journal of Thrombosis and Haemostasis. 8, 2, s. 301-310

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  27. rFVIIa transported from the blood stream into tissues is functionally active

    R. Gopalakrishnan, Ulla Hedner, C. Clark, U. R. Pendurthi & L. V. M. Rao, 2010, I : Journal of Thrombosis and Haemostasis. 8, 10, s. 2318-2321

    Forskningsoutput: TidskriftsbidragLetter

  28. Influence of endothelial cell protein C receptor on plasma clearance of factor VIIa.

    R Gopalakrishnan, U R Pendurthi, Ulla Hedner, H Agersø, C T Esmon & L V M Rao, 2012, I : Journal of Thrombosis and Haemostasis. 10, 5, s. 971-973

    Forskningsoutput: TidskriftsbidragLetter

  29. Pharmacokinetic studies on Wilfactin((R)), a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods

    J Goudemand, I Scharrer, Erik Berntorp, CA Lee, A Borel-Derlon, N Stieltjes, C Caron, JM Scherrmann, F Bridey, Z Tellier, AB Federici & PM Mannucci, 2005, I : Journal of Thrombosis and Haemostasis. 3, 10, s. 2219-2227

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  30. A Randomized Clinical Trial of Prophylaxis in Children with Hemophilia A (the ESPRIT Study).

    A Gringeri, Björn Lundin, S V Mackensen, L Mantovani & P M Mannucci, 2011, I : Journal of Thrombosis and Haemostasis. 9, s. 700-710

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  31. Origin of Swedish hemophilia B mutations

    C. Hallden, Annika Mårtensson, D. Nilsson, Torbjörn Säll, C. Lind-Hallden, A. C. Liden & Rolf Ljung, 2013, I : Journal of Thrombosis and Haemostasis. 11, 11, s. 2001-2008

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  32. Origin of Swedish hemophilia A mutations

    C. Halldén, D. Nilsson, Torbjörn Säll, C. Lind-Hallden, A. C. Liden & Rolf Ljung, 2012, I : Journal of Thrombosis and Haemostasis. 10, 12, s. 2503-2511

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  33. Effects of recombinant human prothrombin on thrombin generation in plasma from patients with haemophilia A and B.

    Kenny M Hansson, David Gustafsson, Tor Skärby, Lars Frison & Erik Berntorp, 2015, I : Journal of Thrombosis and Haemostasis. 13, 7, s. 1293-1300

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  34. Post-translational modifications in proteins involved in blood coagulation.

    Karin M Hansson & Johan Stenflo, 2005, I : Journal of Thrombosis and Haemostasis. 3, 12, s. 2633-2648

    Forskningsoutput: TidskriftsbidragÖversiktsartikel

  35. The role of recombinant factor VIIa(FVIIa) in fibrin structure in the absence of FVIII/FIX

    S He, M Blomback, GJ Ekman & Ulla Hedner, 2003, I : Journal of Thrombosis and Haemostasis. 1, 6, s. 1215-1219

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  36. Potential role of rFVIIa in prophylaxis in severe haemophilia patients with inhibitors.

    Ulla Hedner, 2006, I : Journal of Thrombosis and Haemostasis. 4, Aug 14, s. 2498-2500

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  37. Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?

    C. Hermans, Jan Astermark & P. De Moerloos, 2012, I : Journal of Thrombosis and Haemostasis. 10, 10, s. 2194-2196

    Forskningsoutput: TidskriftsbidragLetter

  38. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays.

    Andreas Hillarp, Kerstin M Gustafsson, Lars Faxälv, Karin Strandberg, Fariba Baghaei, Inger Fagerberg Blixter, Maria Berndtsson & Tomas L Lindahl, 2014, I : Journal of Thrombosis and Haemostasis. 12, 9, s. 1545-1553

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  39. Aspirin resistance is not a common biochemical phenotype explained by unblocked cyclooxygenase-1 activity.

    Andreas Hillarp, Stefan Lethagen & Ingrid Mattiasson, 2003, I : Journal of Thrombosis and Haemostasis. 1, 1, s. 196-197

    Forskningsoutput: TidskriftsbidragLetter

  40. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol.

    Andreas Hillarp, M Stadler, C Haderer, J Weinberger, C M Kessler & J Römisch, 2010, I : Journal of Thrombosis and Haemostasis. 8, s. 2216-2223

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  41. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.

    Andreas Hillarp, F Baghaei, I F Blixter, K M Gustafsson, L Stigendal, M Sten-Linder, Karin Strandberg & T L Lindahl, 2011, I : Journal of Thrombosis and Haemostasis. 9, s. 133-139

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  42. Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays

    Andreas Hillarp, Karin Strandberg, Kerstin M. Gustafsson & Tomas L. Lindahl, 2020 apr 15, I : Journal of Thrombosis and Haemostasis.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  43. Succinate independently stimulates full platelet activation via cAMP and PI3β kinase signaling.

    Carl Högberg, Olof Gidlöf, Chanyuan Tan, Siv Svensson, Jenny Öhman, David Erlinge & Björn Olde, 2011, I : Journal of Thrombosis and Haemostasis. 9, 2, s. 361-372

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  44. Desmopressin (DDAVP) and factor VIII

    Lars Holmberg, 2003, I : Journal of Thrombosis and Haemostasis. 1, 9, s. 2046-2047

    Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

  45. Elevated risk of venous but not arterial thrombosis in Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma

    M. Hultcrantz, R. M. Pfeiffer, M. Bjorkholm, L. R. Goldin, Ingemar Turesson, S. Schulman, O. Landgren & S. Y. Kristinsson, 2014, I : Journal of Thrombosis and Haemostasis. 12, 11, s. 1816-1821

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  46. Fresh frozen plasma reduces thrombin formation in newborn infants

    S Hyytiainen, M Syrjala, Vineta Fellman, M Heikinheimo & J Petaja, 2003, I : Journal of Thrombosis and Haemostasis. 1, 6, s. 1189-1194

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  47. Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice

    Annika Jögi, J Pass, G Hoyer-Hansen, L R Lund, B S Nielsen, K Dano & J Romer, 2007, I : Journal of Thrombosis and Haemostasis. 5, 9, s. 1936-1944

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Föregående 1 2 3 Nästa